For years, obesity rates in the US have gone in one direction: up. From the first year it was launched, Gallup’s National ...

Many doctors and patients came to believe the rise in obesity may be all but biologically inescapable, despite the grave ...

The president’s agreement with drug companies involves a range of prices, depending on dose, product and how you’re paying.

President Trump's plan drops the price of Ozempic and Wegovy for Americans, with plans for Medicare to cover the popular ...

Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Press Release President Donald J. Trump announced agreements with Eli Lilly and Novo Nordisk to reduce prices of available ...

Trump announced new deals with Eli Lilly and Novo Nordisk to lower GLP-1 costs for Medicare, Medicaid, and cash-paying patients.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

A small study helps explain why some people taking Wegovy and similar weight-loss drugs cut back on alcohol, offering insight ...

Under the arrangement, prices for GLP-1 drugs—used both for diabetes and obesity—will be slashed for Medicare and Medicaid beneficiaries. The prices of Ozempic and Wegovy will fall from $1,000 and $1, ...

Novo Nordisk, as well as Eli Lilly, would gain Medicare and Medicaid coverage for their blockbuster weight-loss drugs.

Novo Nordisk Q3 profit drops on restructuring costs as GLP-1 and obesity drug sales rise; company narrows 2025 growth outlook.